BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 22112470)

  • 61. Cancer germline gene activation: friend or foe?
    McFarlane RJ; Feichtinger J; Larcombe L
    Cell Cycle; 2014; 13(14):2151-2. PubMed ID: 25111983
    [No Abstract]   [Full Text] [Related]  

  • 62. Ultimate Precision: Targeting Cancer but Not Normal Self-replication.
    Velcheti V; Schrump D; Saunthararajah Y
    Am Soc Clin Oncol Educ Book; 2018 May; 38():950-963. PubMed ID: 30231326
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [A tumor stem cell-specific marker identified by lineage tracing in the intestine].
    Seno H; Yamaga Y; Nakanishi Y; Chiba T
    Nihon Rinsho; 2015 May; 73(5):850-4. PubMed ID: 25985642
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Metabolic reprogramming of the tumor.
    Ferreira LM; Hebrant A; Dumont JE
    Oncogene; 2012 Sep; 31(36):3999-4011. PubMed ID: 22231450
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Metabolic traits of cancer stem cells.
    Peixoto J; Lima J
    Dis Model Mech; 2018 Jun; 11(8):. PubMed ID: 29991569
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Cancer Stem Cell Biomarker Discovery Using Antibody Array Technology.
    Burgess R; Huang RP
    Adv Clin Chem; 2016; 73():109-25. PubMed ID: 26975971
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Emerging Importance of Survivin in Stem Cells and Cancer: the Development of New Cancer Therapeutics.
    Warrier NM; Agarwal P; Kumar P
    Stem Cell Rev Rep; 2020 Oct; 16(5):828-852. PubMed ID: 32691369
    [TBL] [Abstract][Full Text] [Related]  

  • 68. It is well established that affected intracellular signaling is associated with carcinogenesis, cancer progression and tumor sensitivity to currently existing therapeutic approaches.
    Skvortsova I
    Semin Cancer Biol; 2015 Apr; 31():1-2. PubMed ID: 25559282
    [No Abstract]   [Full Text] [Related]  

  • 69. Tissue design: how Drosophila tumors remodel their neighborhood.
    Patel PH; Edgar BA
    Semin Cell Dev Biol; 2014 Apr; 28():86-95. PubMed ID: 24685612
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Adapting clinical paradigms to the challenges of cancer clonal evolution.
    Murugaesu N; Chew SK; Swanton C
    Am J Pathol; 2013 Jun; 182(6):1962-71. PubMed ID: 23708210
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cancer is an adaptation mechanism of the aged stem cell against stress.
    Tez M
    Rejuvenation Res; 2008 Dec; 11(6):1059-60. PubMed ID: 19072256
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Holistic Approach to Cell Characteristics and Behavioral Analysis.
    Aktug H; Ozdil B; Kocatürk DC; Acikgoz E
    Crit Rev Oncog; 2019; 24(1):21-26. PubMed ID: 31679216
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Surface Markers for the Identification of Cancer Stem Cells.
    Gopalan V; Islam F; Lam AK
    Methods Mol Biol; 2018; 1692():17-29. PubMed ID: 28986883
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Blind source separation methods for deconvolution of complex signals in cancer biology.
    Zinovyev A; Kairov U; Karpenyuk T; Ramanculov E
    Biochem Biophys Res Commun; 2013 Jan; 430(3):1182-7. PubMed ID: 23261450
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Introduction at the special issue on implications of cancer stem/progenitor cell concepts in molecular oncology and novel targeted therapies.
    Mimeault M; Batra SK
    Mol Aspects Med; 2014 Oct; 39():1-2. PubMed ID: 24080440
    [No Abstract]   [Full Text] [Related]  

  • 76. Biomarkers, molecular imaging, and novel therapies of cancer.
    Li M
    Curr Mol Med; 2013 Mar; 13(3):331-2. PubMed ID: 23331004
    [No Abstract]   [Full Text] [Related]  

  • 77. The quest for reliable biomarkers to identify new and recurrent cancer.
    Sauter ER
    Biomark Med; 2012 Oct; 6(5):561-2. PubMed ID: 23075234
    [No Abstract]   [Full Text] [Related]  

  • 78. An overview of new biomolecular pathways in pathogen-related cancers.
    Tornesello ML; Buonaguro L; Buonaguro FM
    Future Oncol; 2015; 11(11):1625-39. PubMed ID: 26043216
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Gene expression 'signature' limitations and genome architecture-based perspectives for robust cancer biomarkers.
    Katsios CS; Papaloukas C; Roukos DH; Baltogiannis G
    Biomark Med; 2013 Feb; 7(1):79-82. PubMed ID: 23387487
    [No Abstract]   [Full Text] [Related]  

  • 80. [The cause of cancer mutations: Improvable bad life or inevitable stochastic replication errors?].
    Alekseenko IV; Kuzmich AI; Pleshkan VV; Tyulkina DV; Zinovyeva MV; Kostina MB; Sverdlov ED
    Mol Biol (Mosk); 2016; 50(6):906-921. PubMed ID: 28064307
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.